Literature DB >> 8862689

Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus.

M Laakso1.   

Abstract

Dyslipidaemia is frequent in non-insulin-dependent diabetes mellitus (NIDDM). Lipid and lipoprotein abnormalities include particularly elevated levels of total and very-low-density lipoprotein (VLDL) triglycerides and reduced levels of high-density lipoprotein (HDL) cholesterol. The worsening of glycaemic control further deteriorates lipid and lipoprotein abnormalities and furthermore, total and low-density lipoprotein (LDL) cholesterol levels are often elevated in poor glycaemic control. Epidemiological data show that total cholesterol is as powerful risk factor for coronary heart disease (CHD) in NIDDM patients as in nondiabetic subjects. High total triglycerides and low HDL cholesterol may be even stronger risk factors for CHD in NIDDM patients than in nondiabetic individuals, but more prospective studies are needed to substantiate this view. Compositional changes in LDL and VLDL particles may further increase the risk of CHD but epidemiological data are missing to support this notion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862689     DOI: 10.3109/07853899608999091

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  4 in total

1.  The correlation between lipids ratio and degree of coronary artery stenosis.

Authors:  Dan Yang; Xianbao Liu; Meixiang Xiang
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-06-01

2.  Smoking influences the association between apolipoprotein E and lipids: the National Heart, Lung, and Blood Institute Family Heart Study.

Authors:  L Djoussé; R H Myers; H Coon; D K Arnett; M A Province; R C Ellison
Journal:  Lipids       Date:  2000-08       Impact factor: 1.880

3.  Dietary magnesium intake and risk of metabolic syndrome: a meta-analysis.

Authors:  D T Dibaba; P Xun; A D Fly; K Yokota; K He
Journal:  Diabet Med       Date:  2014-11       Impact factor: 4.359

Review 4.  Beta-glucans in the treatment of diabetes and associated cardiovascular risks.

Authors:  Jiezhong Chen; Kenneth Raymond
Journal:  Vasc Health Risk Manag       Date:  2008
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.